Week in re­view: Clin­ton over Trump; the hubs have it; we'll al­ways have Paris

End­points as­sess­es the big bio­phar­ma R&D sto­ries of the week, with a lit­tle added com­men­tary on what they mean for the in­dus­try.

 Poll says…Clin­ton over Trump

In our first snap poll of read­ers, one mes­sage came through loud and clear. A large ma­jor­i­ty of sub­scribers to End­points News are less than en­thu­si­as­tic about the idea of a Don­ald Trump pres­i­den­cy. That’s not a big sur­prise, if you con­sid­er the kind of col­lege-ed­u­cat­ed group of in­dus­try read­ers we have in Boston, the Bay Area and Eu­rope. This is not Trump’s base. Hillary Clin­ton, as ex­pect­ed, does well. But the 20% of re­spon­ders, out of more than 500, who said there’s no dif­fer­ence be­tween the two al­so un­der­scores just how dis­en­chant­ed many US vot­ers are this year. Our en­dorse­ment? Any­body but Trump, and Clin­ton has the on­ly vi­able shot at be­ing that per­son.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE